Compare BUI & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUI | NPCE |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.6M | 514.3M |
| IPO Year | N/A | 2021 |
| Metric | BUI | NPCE |
|---|---|---|
| Price | $25.76 | $17.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 59.8K | ★ 224.5K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 6.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | N/A | ★ $94,864,000.00 |
| Revenue This Year | N/A | $24.82 |
| Revenue Next Year | N/A | $0.77 |
| P/E Ratio | $7.77 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $18.73 | $7.56 |
| 52 Week High | $24.22 | $18.98 |
| Indicator | BUI | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 65.15 |
| Support Level | $25.59 | $15.03 |
| Resistance Level | $26.05 | $16.33 |
| Average True Range (ATR) | 0.52 | 0.69 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 34.69 | 79.03 |
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing of writing (selling) call and put options.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.